Oral chronic graft versus host disease (cGVHD) is often refractory to systemic therapies. Additional topical treatment is commonly required. The potency of the agent, the vehicle and formulation in which it is delivered are all critical factors in determining the effectiveness of topical therapies. High potency of budesonide, combined with its very low bioavailability when absorbed through mucosal surfaces, increased the potential role in topical application for oral cGVHD. Viscous formulation increases mucosal contact time resulting in a greater decrease in mucosal inflammation. This short communication suggests that oral viscous budesonide should be considered as a potential new therapy in the management of oral cGVHD.

Bertelli, L., Di Nardo, G., Zama, D., Bardasi, G., Morello, W., Masetti, R., et al. (2016). A New Formulation of an Old Drug: A Potential New Therapy in the Management of Oral cGvHD. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 38(8), E295-E297 [10.1097/MPH.0000000000000618].

A New Formulation of an Old Drug: A Potential New Therapy in the Management of Oral cGvHD

Morello, William;Masetti, Riccardo;
2016

Abstract

Oral chronic graft versus host disease (cGVHD) is often refractory to systemic therapies. Additional topical treatment is commonly required. The potency of the agent, the vehicle and formulation in which it is delivered are all critical factors in determining the effectiveness of topical therapies. High potency of budesonide, combined with its very low bioavailability when absorbed through mucosal surfaces, increased the potential role in topical application for oral cGVHD. Viscous formulation increases mucosal contact time resulting in a greater decrease in mucosal inflammation. This short communication suggests that oral viscous budesonide should be considered as a potential new therapy in the management of oral cGVHD.
Articolo in rivista - Articolo scientifico
cGvHD; familial hemophagocytic lymphohistiocytosis; oral viscous budesonide; topical medications;
cGvHD; familial hemophagocytic lymphohistiocytosis; oral viscous budesonide; topical medications; Administration, Topical; Budesonide; Child; Chronic Disease; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Mouth Diseases; Mouth Mucosa; Oral Ulcer; Pediatrics, Perinatology and Child Health; Hematology; Oncology
English
2016
38
8
E295
E297
none
Bertelli, L., Di Nardo, G., Zama, D., Bardasi, G., Morello, W., Masetti, R., et al. (2016). A New Formulation of an Old Drug: A Potential New Therapy in the Management of Oral cGvHD. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 38(8), E295-E297 [10.1097/MPH.0000000000000618].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/205551
Citazioni
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
Social impact